<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521092</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00229</org_study_id>
    <secondary_id>NCI-2009-00229</secondary_id>
    <secondary_id>CASE 1706 - AMC 049</secondary_id>
    <secondary_id>CDR0000561751</secondary_id>
    <secondary_id>CASE 1706 / AMC 049</secondary_id>
    <secondary_id>7831</secondary_id>
    <secondary_id>U01CA062502</secondary_id>
    <secondary_id>P30AI036219</secondary_id>
    <nct_id>NCT00521092</nct_id>
  </id_info>
  <brief_title>Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma</brief_title>
  <official_title>Phase II Study of Sunitinib (SU11248) in Patients With Kaposi's Sarcoma in East Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth and by blocking blood flow to the tumor. This phase II trial is studying the&#xD;
      side effects and how well sunitinib malate works in treating patients with Kaposi sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the clinical response of sunitinib malate in patients with Kaposi sarcoma (KS)&#xD;
      in Uganda and Kenya.&#xD;
&#xD;
      II. Compare clinical response rates in endemic versus epidemic (AIDS) KS. III. Determine the&#xD;
      safety and tolerability of sunitinib malate in patients with endemic or epidemic (AIDS) KS.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I Monitor the impact of sunitinib malate on underlying HIV-1 and Kaposi sarcoma-associated&#xD;
      herpesvirus (KSHV) viral infection (HIV-1 plasma RNA and KSHV cell-associated DNA).&#xD;
&#xD;
      II. Evaluate morphological changes in KS lesions after treatment. III. Determine the&#xD;
      pharmacokinetic profile of sunitinib malate in patients with KS.&#xD;
&#xD;
      IV Evaluate KSHV gene expression in endemic and epidemic KS lesions in patients in Uganda and&#xD;
      Kenya.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to HIV-serostatus&#xD;
      (endemic [HIV-seronegative] vs epidemic [HIV-seropositive/AIDS] kaposi sarcoma).&#xD;
&#xD;
      Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every&#xD;
      6 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo tumor tissue and blood sample collection periodically for correlative and&#xD;
      pharmacokinetic studies. Samples are analyzed for CD4 lymphocyte counts, HIV-1 plasma RNA&#xD;
      levels, KSHV specific antibodies, expression pattern of KSHV in vitro and in vivo, expression&#xD;
      of latently versus lytically expressed genes in tumor tissue, and plasma concentrations of&#xD;
      sunitinib malate and its active metabolite, SU12662.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled.&#xD;
  </why_stopped>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>The true response rate will be estimated based on the number of responses using a binomial distribution. The confidence intervals for them can be estimated using same distribution. Chi-square test or Fisher's exact test will be used to examine the difference of response rate between the two cohorts and log-rank test for the difference of survival outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of treatment to date of death, assessed up to 11 months</time_frame>
    <description>Will be estimated by Kaplan-Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From the date of treatment to date of death or date of disease progression, assessed up to 11 months</time_frame>
    <description>Will be estimated by Kaplan-Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of plasma-associated HIV-1 RNA viral load and cell-associated KSHV DNA viral load</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Multivariate analysis will be performed using the Cox proportional hazards model. The effects of CD4+ lymphocyte counts, plasma HIV-1 RNA viral load and KSHV DNA level on the objective response rate will be evaluated using multivariate logistic regression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4+ and CD8+ cell counts, levels of plasma-associated HIV-1 RNA, and cell-associated KSHV DNA load</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>For each treatment cohort and for all groups combined, the Wilcoxon signed rank test (the non-parametric version of paired T-test) will be used to evaluate the changes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>AIDS-related Kaposi Sarcoma</condition>
  <condition>Classic Kaposi Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>SU11248</other_name>
    <other_name>sunitinib</other_name>
    <other_name>Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Documented HIV-serostatus [HIV-seronegative (endemic KS) or HIV-seropositive&#xD;
             (epidemic/AIDS KS)]&#xD;
&#xD;
          -  No symptomatic organ involvement, visceral crisis, or life-threatening disease (e.g.,&#xD;
             extensive or symptomatic pulmonary disease or reticuloendothelial system/hepatic&#xD;
             involvement) for which aggressive double- or triple-drug combination chemotherapy for&#xD;
             urgent cytoreduction is indicated (i.e., doxorubicin hydrochloride, bleomycin, and&#xD;
             vinblastine [ABV], BV, or AV)&#xD;
&#xD;
          -  Histologically confirmed Kaposi sarcoma&#xD;
&#xD;
          -  Platelet count &gt; 75,000/uL&#xD;
&#xD;
          -  Life expectancy &gt;= 24 weeks&#xD;
&#xD;
          -  Absolute granulocyte count &gt; 1,000/uL&#xD;
&#xD;
          -  Hemoglobin &gt; 8.0 g/dL OR hematocrit &gt; 24%&#xD;
&#xD;
          -  Serum creatinine =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  AST &lt; 3 times normal&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Normal clinical cardiac examination and normotensive (systolic and diastolic BP &lt;&#xD;
             140/90 mm Hg) documented on at least two occasions prior to enrollment&#xD;
&#xD;
          -  Normal ECG including QTc interval &lt; 500 msec&#xD;
&#xD;
          -  Normal echocardiogram prior to enrollment (if feasibly possible)&#xD;
&#xD;
          -  Must be able to swallow study medication&#xD;
&#xD;
          -  No acute infections [Patients with chronic infections (e.g., malaria, tuberculosis,&#xD;
             parasitic infections, or hepatitis B or C) that may be active but under treatment are&#xD;
             allowed provided all eligibility criteria are met]&#xD;
&#xD;
          -  At least 60 days since prior local treatment modalities (e.g., resection, cryosurgery,&#xD;
             radiotherapy, or intralesional therapy) AND treated lesions must have clearly&#xD;
             progressed following such therapies if the lesions are to be used as an index lesion&#xD;
&#xD;
          -  No prior systemic anticancer therapy for Kaposi sarcoma&#xD;
&#xD;
          -  Concurrent antiretroviral therapy required for HIV-seropositive patients (Patient must&#xD;
             be on a stable regimen 8 weeks prior to study enrollment--An exception may be made for&#xD;
             patients who have exhausted or are intolerant to all available regimens)&#xD;
&#xD;
          -  No other concurrent systemic anticancer therapy&#xD;
&#xD;
          -  Patient resides in Uganda or Kenya, East Africa&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Baseline diarrhea &gt;= grade 2 by CTCAE&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, any of the following:&#xD;
&#xD;
               -  Ongoing or acute active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure (NYHA class III or IV heart disease)&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, any of the following:&#xD;
             1) Cardiac arrhythmia (i.e., history of serious ventricular arrhythmia, ventricular&#xD;
             fibrillation, or ventricular tachycardia &gt;= 3 beats in a row OR QTc &gt;= 500 msec) 2)&#xD;
             Psychiatric illness or social situation that would limit compliance with study&#xD;
             requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scot Remick</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>August 24, 2007</study_first_submitted>
  <study_first_submitted_qc>August 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2007</study_first_posted>
  <last_update_submitted>May 2, 2014</last_update_submitted>
  <last_update_submitted_qc>May 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

